What to Expect During an FDA Quality System Inspection

As a medical device developer, when the time comes for an FDA inspection, it is entirely normal to feel a surge of pressure. Complex regulations and quality standards shouldn’t slow you down. With the FDA’s full transition to the Quality Management System Regulation (QMSR) as of February 2, 2026, understanding exactly how the FDA evaluates your facility under the new rules allows you to transform a stressful event into a smooth, manageable process.

In this blog, we simplify the inspection process so you know exactly what to expect. Here are the key takeaways we will cover:

• How FDA investigators assess your Quality Management System (QMS) implementation.
• The specific, high-priority records and processes investigators will review.
• Common pitfalls and compliance gaps that trigger regulatory warnings.
• Actionable steps to prepare your team and facility for a successful audit.

How FDA Investigators Evaluate Quality System Implementation

FDA investigators do not just look for isolated mistakes; they evaluate whether your organization embraces a culture of quality. The FDA has officially retired the Quality System Inspection Technique (QSIT). Today, inspections follow Compliance Program 7382.850, which utilizes a risk-based evaluation of your entire QMSR, now fully harmonized with ISO 13485:2016.

Instead of predefined subsystem sampling, investigators now apply critical thinking to identify product risks that could adversely impact patients. Depending on your firm’s history, they will use one of two models. Model 1 is used for routine surveillance and targets at least one high-risk element per area based on patient safety. Model 2 is a comprehensive inspection used for new firms or premarket approval (PMA) audits. The goal is to confirm you consistently use risk-based decision-making throughout the device lifecycle.

Key Documentation and Process Areas Commonly Reviewed

To ensure a seamless pathway to market, you must keep your documentation organized and aligned with the QMSR framework. Investigators now organize their audits around six QMS Areas and four Other Applicable FDA Requirements (OAFRs).

The six QMS Areas are: Change Control; Design and Development; Management Oversight; Measurement, Analysis, and Improvement; Outsourcing and Purchasing; and Production and Service Provision. Crucially, under the QMSR, the FDA now has the authority to inspect records that were previously exempt. Investigators will thoroughly examine your internal quality audits, supplier audit reports, and management review records to ensure executive management is actively overseeing quality. They will also verify your compliance with OAFRs, such as Medical Device Reporting (MDR) and Unique Device Identification (UDI).

Typical Findings That Lead to Warning Letters or Observations

Small gaps in your compliance strategy can inadvertently create major roadblocks. When investigators find significant issues, they issue a Form 483 observation categorized as Voluntary Action Indicated (VAI) or Official Action Indicated (OAI).

Under the new inspection paradigm, the most frequent pitfalls occur when companies fail to integrate risk-based thinking into their daily operations. Failing to separate Corrective Action from Preventive Action procedures, as required by ISO 13485, will quickly draw a citation. Other common triggers include treating all suppliers equally rather than using risk-proportionate evaluations, or failing to validate software and manufacturing processes in proportion to patient risk. Addressing these compliance challenges directly before an inspector arrives prevents costly delays and protects your market launch.

Preparing Teams and Facilities for Inspection Readiness

Our proven process makes it easy to get started with inspection readiness. You can protect your timelines and budget by taking a few clear, manageable steps right now:

1. Conduct Internal Audits: Regularly audit your own processes to identify and fix compliance risks before the FDA arrives.
2. Designate an Inspection Team: Assign specific roles, including an inspection host to guide the investigator, a scribe to take notes, and subject matter experts to answer technical questions.
3. Organize Your Logistics: Set up a dedicated “front room” for the investigator to review documents and a “back room” where your team gathers and reviews requested files before presenting them.
4. Train Your Staff: Ensure non-technical workers and technical experts alike know how to answer investigator questions directly, honestly, and without guessing.

The Importance of Proactive Compliance

Developing and launching a medical device is hard enough without the threat of a failed inspection. Proactive compliance is not just about avoiding warning letters; it is a strategic advantage that accelerates your market launch and builds trust with users. MedLaunch provides unparalleled expertise and step-by-step guidance to ensure your facility is fully prepared. By building a strong QMS foundation early, you can face any FDA inspection with total confidence.

Ready to prepare your team for a successful inspection? Contact MedLaunch today for guidance.

Tags: FDA quality inspection, FDA submissions, QMS